The pharmaceutical landscape is constantly evolving, with new therapeutic agents emerging to address unmet medical needs. Atogepant, a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, represents a significant advancement in the management of migraine. As the demand for such innovative treatments grows, so does the critical need for their essential chemical precursors, including intermediates like the one identified by CAS number 1455358-12-9.

The synthesis of Atogepant is a multi-step process, and the intermediate 1-(tert-butyl)-3-((5-chloro-3-(chloromethyl)pyridin-2-yl)methyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one is a crucial component in this complex chain. Its chemical structure (C18H19Cl2N3O, MW 364.27) and high purity (typically 98% assay) are vital for ensuring the efficiency and success of the downstream reactions. Pharmaceutical companies and research institutions rely on consistent access to such intermediates to drive forward their development pipelines.

NINGBO INNO PHARMCHEM CO.,LTD. plays a key role in this ecosystem as a dedicated manufacturer and supplier of high-quality pharmaceutical intermediates. We understand that the future of therapeutic development hinges on reliable access to these building blocks. Our commitment is to provide a stable supply of CAS 1455358-12-9, enabling researchers and manufacturers to secure the materials they need to produce Atogepant and potentially other related compounds. We aim to be the go-to source when you need to buy this critical chemical.

The competitive price and unwavering quality offered by Chinese manufacturers like NINGBO INNO PHARMCHEM CO.,LTD. are significant factors for global pharmaceutical companies. By maintaining robust quality control and efficient production processes, we ensure that our clients receive intermediates that meet stringent international standards. As Atogepant and similar therapies continue to gain traction, the demand for intermediates like CAS 1455358-12-9 will only increase. Partnering with a reliable manufacturer now ensures readiness for future growth and innovation in pharmaceutical development.